

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of annual general meeting (the “Original Notice”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “Company”) will be convened and held at 1202B, 12/F, Building 3, No. 22 Ronghua Middle Road, Beijing Economic-Technological Development Area, Beijing, PRC on Friday, 26 June 2026 at 3:00 p.m. (the “AGM”) and this supplemental notice shall be read together with the Original Notice. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Original Notice and the supplemental circular of the Company dated 11 June 2026 (the “**Supplemental Circular**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT:

Due to the matters as set out in the Supplemental Circular, the resolutions under items numbered 7, 14 and 15 in the Original Notice have been withdrawn and will not be submitted to the AGM for approval by the Shareholders.

Apart from the amendments set out above, all information contained in the Original Notice shall remain to have full force and effect.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, 11 June 2026

Notes:

1. Details of the resolutions stated above are set out in the Supplemental Circular. No revised form of proxy will be issued by the Company.
2. Apart from the withdrawal of the Ordinary Resolution and Special Resolutions and other information as set out in the Supplemental Circular, all other matters to be dealt with at the AGM remain unchanged. For details of the other resolutions to be considered and approved at the AGM, eligibility for attending/voting at the AGM, closure of register of members of the Company and other relevant matters, please refer to the circular of the Company dated 28 May 2026 and the Original Notice.

As at the date of this notice, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.